A report from the Chinese Center for Disease Control and Prevention on January 15 showed that, based on optional nucleic acid testing data, positive cases across the country have showed a clear trend of increasing then decreasing since December 9 of last year.
A final list of drugs to be included in China's public health insurance scheme was released on January 18. A total of 111 drugs had been added to the catalogue, and that three drugs had been dropped.
Junshi Biosciences, a Chinese biopharmaceutical company, announced on January 18 that the country's medical products authorities had accepted a new drug application for Deuremidevir Hydrobromide Tablets (project code: JT001/VV116) for the treatment of COVID-19.
Talks between Chinese regulators and US pharmaceutical company Pfizer regarding the potential inclusion of Paxlovid, an orally administered COVID-19 medication, in the country's public health insurance scheme have broken down.
Hangzhou-based tech giant Alibaba has launched a special campaign to provide free COVID-19 consultation services for rural areas, support the training of grassroots medical staff, and donate urgently needed medicines and medical devices to 22 underdeveloped counties across the country.
A Chinese web user posted that they had put Huawei's smart watch product on a ham sausage, and it actually showed blood oxygen saturation data.
Due to the rapid increase of COVID-19 infection cases in China, the demand for Pfizer's pill Paxlovid has also greatly increased. As the drug is being hyped by drug scalpers, the price of Paxlovid on third-party channels has climbed to tens of thousands of yuan, which is nearly six times more expensive than the normal price of 2,000 yuan ($287).
China's National Health Commission announced in a statement on December 26 that mandatory testing and quarantine for international arrivals will be canceled and Chinese citizens' outbound tourism will be resumed in an orderly manner.
As COVID-19 cases rise rapidly in China following a loosening of pandemic control measures, the country's logistics networks are now facing unprecedented challenges.
Nieng Yan, a Chinese structural biologist and dean of the Shenzhen Medical Academy of Research and Translation, stated in a December 18 Weibo post that family is one of the main reasons behind her recent return to China, also discussing her parents' experience of being infected by COVID-19.
On the afternoon of December 12, Chinese logistics service provider SF Express emerged as a trending topic on Chinese social media outlet Weibo because its mini program and PC page crashed. After some emergency repairs, the company's services went back to normal.
With the recent relaxation of the Chinese government's zero COVID policy, drugs for flu symptoms and fever such as Ibuprofen and Lianhua Qingwen, antigen test kits and vitamin C tablets are out of stock in pharmacies and e-commerce platforms.
Due to COVID-19 pandemic prevention requirements, two factories in Hefei, Anhui Province of NIO, a leading Chinese new energy automobile manufacturer, have stopped production recently. As a result, delivery of its models will be delayed.
Crowds of Foxconn employees walked along the highway to their hometowns due to an outbreak of COVID-19 cases at the world's largest iPhone manufacturing facility in Zhengzhou. This factory is currently the leading source of employment in the central Chinese city of over 10 million people.
Various Chinese social media accounts spread a message recently stating that travelers stranded in Xinjiang due to an ongoing surge in COVID cases could consider finding jobs in the local area. Local authorities said the message was a misinterpretation of the current situation.
Shenzhen-based automotive firm BYD, which has recently faced reports of Warren Buffett's share reduction, released its latest sales data on September 2. In August, BYD's total sales reached a new high.
Chinese internet giant Tencent logged its first-ever quarterly revenue fall along with declining net profit for the fourth consecutive quarter, according to its second-quarter 2022 results released on August 17.
Chinese electric vehicle startup Li Auto saw its losses widen in the second quarter of the year, according to its periodic fiscal disclosure on August 15, which also provided soft guidance for the third quarter.
The China Passenger Car Association (CPCA) said on July 22 that according to the data of manufacturers' retail target survey and weekly sales trend in July, the retail sales volume of passenger cars in July is estimated to be 1.77 million units.
According to statistics released by the China Passenger Car Association Cars (CPCA) on Friday, the sales volume of domestic passenger cars reached 1.354 million units in May, down 16.9% year-on-year.